Historical position

Daniel Loeb’s United Therapeutics Corp Del (UTHR) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Third Point LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2006Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares450.00KHighest verified quarter-end share count
Quarters reported3Verified quarters with shares above zero
What happened?

Third Point LLC first reported United Therapeutics Corp Del in Q2 2006. The reported position was increased across later filings. Verified positive position history runs through Q2 2007. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2007
New position+250.00K shares · 250.00K shares reported
Filing context

Quarter-end price $63.76 · Estimated holding basis $63.76

Q4 2006
Sold the entire position−450.00K shares · No shares reported at quarter-end
Q3 2006
Bought 350.0% more+350.00K shares · 450.00K shares reported after the change
Filing context

Quarter-end price $52.54 · Estimated holding basis $53.70

Q2 2006
New position+100.00K shares · 100.00K shares reported
Filing context

Quarter-end price $57.77 · Estimated holding basis $57.77

Portfolio importance

How important was United Therapeutics Corp Del in Third Point LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.3%Q2 2007
Last reported rank#71of 92 reported positions
Peak portfolio weight1.1%Q3 2006
Best historical rank#29Q3 2006
At peak importanceQ3 2006
UTHR
1.1%
Largest holding
10.9%
Cross-investor discovery

Who else owns United Therapeutics Corp Del?

Also reported by 2 other tracked investors in their latest verified filings.

Ray DalioBridgewater Associates, LP
UTHR0.2% of reported portfolio
Joel GreenblattGotham Asset Management
UTHR0.1% of reported portfolio
Explore United Therapeutics Corp Del across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$497.112026-09-11

Market context only; not an investor transaction price.

Latest filing quarter-end price$63.76Q2 2007

Derived from validated reported value and shares where supported.

Estimated holding basis$63.76Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Third Point LLC’s Form 13F disclosures, not Daniel Loeb’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.